NIAID Awards $2M for DARE-HPV; Patent Expands IP Foundation
What happened
The National Institute of Allergy and Infectious Diseases provided a $2.0 million award for DARE-HPV. Concurrently, the United States Patent and Trademark Office issued U.S. Patent No. 12,678,439 to Douglas Pharmaceuticals Limited, a licensor to Daré Bioscience, Inc. This patent covers pharmaceutical compositions of lopinavir and ritonavir for topical treatment of HPV-related cervical pathologies.
From manilatimes.net
Why it matters
DARE-HPV is being developed as a potential first-in-category treatment for high-risk HPV infection, addressing a current treatment gap for U.S. women. The program has received approximately $10 million in non-dilutive ARPA-H funding alongside the NIAID award.
FDA approval is the goal for product candidates from Daré Bioscience, Inc.
From manilatimes.net
Who's involved
- National Institute of Allergy and Infectious DiseasesProvided a $2.0 million award to support the DARE-HPV research program
- United States Patent and Trademark OfficeIssued U.S. Patent No. 12,678,439 covering the pharmaceutical compositions
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
The National Institute of Allergy and Infectious Diseases could see increased research funding and contracts in the infectious disease sector
- United States Patent and Trademark OfficeSpeculative
The United States Patent and Trademark Office could see increased revenue and filings related to pharmaceutical intellectual property
Keep exploring
The entities involved
-
National Institute of Allergy and Infectious Diseases
US research institute for the treatment and prevention of infectious diseases